Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ivax Launches Neurontin Generic “At Risk” As Pregabalin User Fee Date Nears

Executive Summary

Ivax' "at risk" launch of generic gabapentin comes less than two weeks before the anticipated FDA user fee date for Pfizer's Neurontin follow-on drug Lyrica
Advertisement

Related Content

Pfizer Recalls One Neurontin Lot; Puerto Rico Plant Still Under Consent Decree
Pfizer Recalls One Neurontin Lot; Puerto Rico Plant Still Under Consent Decree
Generic Price War Remains Strong; Intensity Is Product Specific, Firms Say
Generic Price War Remains Strong; Intensity Is Product Specific, Firms Say
Pfizer’s “Swift Response” To Neurontin Generics Gives Greenstone 23% Share
Pfizer’s Lyrica: “Approvable” For Three Indications, Not Generalized Anxiety
Pfizer Sees 5% Growth In Second Half; Currency, Competition Hurt Sales
Teva, Ivax Move Closer To Marketing Generic Gabapentin
Teva, Ivax Move Closer To Marketing Generic Gabapentin
Pfizer Could Launch Three Significant NMEs in 2004; Will Any Surpass Viagra?

Topics

Advertisement
UsernamePublicRestriction

Register

PS044546

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel